Next FDA PCAC Meeting (by Feb 2027): GHK-Cu, LL-37, Dihexa, Melanotan II, PEG-MGF

Key takeaways

FDA has posted an early announcement: the Pharmacy Compounding Advisory Committee will meet “before the end of February 2027”. No date, Federal Register notice or docket existed as of 11 November 2026.
Five substances are on the agenda for possible 503A bulks-list inclusion: cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II and PEG-MGF.
FDA’s compounding safety page already carries concerns for all five, ranging from immunogenicity and impurity risk to having found no human exposure data.
Committee votes are non-binding. In 2026, though, HHS turned a favourable July vote into an enforcement policy within about three months.

Which peptides will FDA’s compounding committee review next?

FDA’s meeting page says the Pharmacy Compounding Advisory Committee (PCAC) will discuss five bulk drug substances “being considered for inclusion on the 503A bulks list”: cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II and pegylated mechano growth factor (PEG-MGF). FDA says it “will host an advisory committee meeting before the end of February 2027” and that the “time and location will be scheduled in the coming months” (FDA meeting page).

A Federal Register search on 11 November 2026 returned no meeting notice yet (Federal Register API). FDA’s 2027 meeting-materials page holds only the early announcement (FDA).

Why does this meeting matter more after July 2026?

Because of what happened last time. The PCAC met on 23–24 July 2026 to review BPC-157, KPV, TB-500, MOTS-c, emideltide, semax and epitalon-related substances (Federal Register notice). FDA’s drug centre recommended against listing them. According to HHS, the committee voted in favour of inclusion for the six that HHS later covered (HHS Appendix B).

On 28 October HHS issued an enforcement discretion policy for those six, citing the committee’s recommendations. Emideltide was not included. That is explained in HHS’s peptide compounding policy explained. The sequence doesn’t predict how the next meeting will go. It does show that a favourable vote can change access in months, before any rulemaking.

How did the July 2026 agenda end up?

The July review is the closest guide to what the next one could produce, so here is how each substance on that agenda ended up by November. Routes are as set out in the HHS policy and summarised in NABP’s 28 October memo to state boards (HHS Appendix B; NABP memo).

July 2026 substance	Outcome by 11 Nov 2026	Routes covered
BPC-157	In the HHS policy (as BPC-157 acetate)	Subcutaneous, intramuscular, oral, topical
TB-500	In the HHS policy (as TB-500 acetate)	Subcutaneous or intramuscular injection
Epitalon	In the HHS policy (as epitalon acetate)	Subcutaneous or intramuscular, dispensed in intermittent courses
MOTS-c	In the HHS policy (as MOTS-c acetate)	Subcutaneous or intramuscular injection
KPV	In the HHS policy (as KPV acetate)	Topical and oral
Semax	In the HHS policy (as semax free base)	Intranasal
Emideltide (DSIP)	Not included	—

Two lessons carry over. First, HHS did not cover every route that was nominated. It limited each peptide to specific routes and a specific salt form. Second, none of the six is on the bulks list. All six sit under a non-binding interim policy that HHS says it may revisit. If HHS were to act on a future vote, July shows the form that action has taken so far: route by route and salt by salt. Nothing requires HHS or FDA to act at all.

What has FDA already said about each of the five?

All five appear on FDA’s compounding safety page under nominations that were withdrawn from 503A category 2. The page is current as of 22 April 2026, and FDA’s safety statements remain on it (FDA). Quoted here as FDA’s views:

Substance	FDA’s stated concern
Cathelicidin (LL-37)	“May pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization.” FDA says it “lacks sufficient safety-related information” and that “nonclinical research findings suggest detrimental effects on male reproduction and that this drug can be protumorigenic in some tissues.”
GHK-Cu (injectable routes)	“Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans to inform safety-related considerations.”
Dihexa acetate	“FDA has not identified any human exposure data on drug products containing dihexa acetate administered via any route of administration.”
Melanotan II	“May pose risk for immunogenicity for certain routes of administration due to the potential for aggregation or peptide-related impurities. Published case reports discuss serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism.”
PEG-MGF	“May pose significant risk for immunogenicity for certain routes of administration”. FDA “has not identified any human exposure data on drug products containing PEG-MGF administered via any route.”

For comparison, FDA’s statements on the July group were similar. Its TB-500 entry, for example, also says FDA found no human exposure data (FDA). HHS covered TB-500 anyway, as explained in TB-500’s regulatory status.

Does this affect cosmetic GHK-Cu?

The FDA entry quoted above is limited to injectable routes of administration (FDA), and the PCAC agenda concerns the 503A bulks list for compounded drugs (FDA). Copper peptides in cosmetics are regulated under separate rules that this article does not cover. Research-use GHK-Cu sold online is a third channel again; see research-use-only vs compounded vs FDA-approved peptides.

What would a vote do, and what wouldn’t it do?

Outcome	Legal effect on its own	What could follow
Vote in favour	None. Advisory committees make “non-binding recommendations” (FDA)	FDA could propose adding the substance to the bulks list through rulemaking, and HHS could extend an interim policy, as it did in October 2026
Vote against	None	The substance stays off the bulks list. FDA’s safety statements remain
No vote / agenda change	None	Status quo. FDA can change an agenda before a meeting

The bulks list itself only changes by final rule. FDA’s 503A page shows no proposed rule adding any peptide (FDA). Our regulatory tracker logs each step.

How can the public take part?

FDA says it “intends to publish a Federal Register notice and establish a docket for public comment on this meeting in the near future”. The notice will explain how to request a slot in the open public hearing (FDA). FDA also says:

the meeting will be available online, and CDER plans a live webcast;
webcast details will be posted “no later than two business days” before the meeting;
if materials cannot be posted in advance, they will be made public at the time of the meeting.

Briefing documents set out FDA’s analysis of each substance, so their posting is the first concrete signal to watch.

Does any of this change sports rules?

No. Compounding status and anti-doping status are separate. USADA’s 2027 advisory says that on the 2027 Prohibited List “‘peptides’ in general are now named as prohibited substances in the S0 class”, and that even an unnamed peptide “may still be prohibited” (USADA). Athletes should check with their anti-doping organisation for any specific substance.

What should readers watch for, in order?

The Federal Register meeting notice, giving the date, docket number and comment instructions.
FDA briefing documents, where FDA’s recommendation on each substance appears.
The votes, substance by substance and route by route. In July, routes mattered: HHS later limited each peptide to specific routes.
Any HHS action afterwards. The October policy is the precedent.

Suppliers that sell any of these five for laboratory research should note that none of these steps would change research-use-only rules. Listed suppliers and their published testing evidence are in our supplier directory.

Sources

Checked 11 November 2026. This page describes regulatory process only. It is not medical or legal advice and makes no claims about the safety or effects of any substance.

Reader Question

“Is GHK-Cu or LL-37 going to be added to the HHS peptide list?”

Short Answer

Nobody knows yet. FDA’s committee will review them by the end of February 2027. Its vote is non-binding, and FDA’s published safety concerns for both are still on its website.

Practical Recommendation

Watch the Federal Register for the PCAC meeting notice. That is when the date and docket become official.
Read FDA’s briefing documents for its recommendation on each substance and route.
Treat any vote as advice. Compounding access changes only through a final rule or a new HHS policy.

What we learned

FDA’s written view on all five substances is already public, and it reads much like its view on the July group before HHS overrode it. The briefing documents and the route-by-route votes are where real information will appear. Until then, any claim that GHK-Cu or LL-37 is “about to be legal” is a forecast, not a fact.

Frequently asked

When is the next FDA compounding committee meeting on peptides?

FDA says before the end of February 2027. As of 11 November 2026 no date had been set and no Federal Register notice had been published.

Which peptides are on the next PCAC agenda?

Cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II and PEG-MGF, for possible inclusion on the 503A bulks list.

Will GHK-Cu become legal to compound?

Not because of a vote alone. Committee recommendations are non-binding. Bulks-list changes require a final rule, although HHS could issue another interim enforcement policy, as it did in October 2026.

Does the vote affect research-use-only peptides?

No. The committee advises on compounding by licensed pharmacies and physicians. Research-use-only sales are outside that process.

Can the public comment?

Yes. FDA says it will open a docket and explain how to request a speaking slot in its Federal Register notice for the meeting.

Explore the directory

Compare companies, suppliers and testing laboratories in the Peptide Ad Lab index. Every profile separates what we verified from what a company claims.

Browse companies Supplier comparisons Testing facilities

Which Peptides Are Next? FDA’s 2027 Compounding Committee Agenda: GHK-Cu, LL-37, Dihexa, Melanotan II and PEG-MGF